119 related articles for article (PubMed ID: 35093625)
1. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
Chang J; Wu YL; Lu S; Wang J; Mok T; Zhang L; Feng J; Wu L; Tu HY; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Poddubskaya E; Soo RA; Chia YH; Penrod JR; Taylor F; Lawrance R; Blum SI; Sun X; Juarez-Garcia A; Moreno-Koehler A; Li A; Li A; Cheng Y
Lung Cancer; 2022 Mar; 165():71-81. PubMed ID: 35093625
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S; Wang J; Cheng Y; Mok T; Chang J; Zhang L; Feng J; Tu HY; Wu L; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Ying K; Zhong H; Poddubskaya E; Soo RA; Chia YH; Li A; Li A; Wu YL
Lung Cancer; 2021 Feb; 152():7-14. PubMed ID: 33321441
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Reck M; Taylor F; Penrod JR; DeRosa M; Morrissey L; Dastani H; Orsini L; Gralla RJ
J Thorac Oncol; 2018 Feb; 13(2):194-204. PubMed ID: 29129758
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
10. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Cheng Y; Sakai H; Paz-Ares L; Lu S; John T; Sun X; Moisei A; Taylor F; Lawrance R; Zhang X; Sylvester J; Yuan Y; Blum SI; Penrod JR; Carbone DP
Eur J Cancer; 2023 Apr; 183():174-187. PubMed ID: 36871487
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
13. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Audigier-Valette C; Zurawski B; Linardou H; Otterson GA; Salman P; Nishio M; de la Mora Jimenez E; Lesniewski-Kmak K; Albert I; Ahmed S; Syrigos K; Penrod JR; Yuan Y; Blum SI; Nathan FE; Sun X; Moreno-Koehler A; Taylor F; O'Byrne KJ
J Thorac Oncol; 2021 Apr; 16(4):665-676. PubMed ID: 33485960
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer RJ; Escudier B; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Plimack ER; Procopio G; McDermott DF; Castellano D; Choueiri TK; Donskov F; Gurney H; Oudard S; Richardet M; Peltola K; Alva AS; Carducci M; Wagstaff J; Chevreau C; Fukasawa S; Tomita Y; Gauler TC; Kollmannsberger CK; Schutz FA; Larkin J; Cella D; McHenry MB; Saggi SS; Tannir NM
Cancer; 2020 Sep; 126(18):4156-4167. PubMed ID: 32673417
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
16. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
[TBL] [Abstract][Full Text] [Related]
17. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Antonia SJ; Borghaei H; Ramalingam SS; Horn L; De Castro Carpeño J; Pluzanski A; Burgio MA; Garassino M; Chow LQM; Gettinger S; Crinò L; Planchard D; Butts C; Drilon A; Wojcik-Tomaszewska J; Otterson GA; Agrawal S; Li A; Penrod JR; Brahmer J
Lancet Oncol; 2019 Oct; 20(10):1395-1408. PubMed ID: 31422028
[TBL] [Abstract][Full Text] [Related]
18. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
